Vir Biotechnology, Inc. (Nasdaq: VIR) has announced that three abstracts highlighting new data from its chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2024, scheduled for June 5-8 in Milan, Italy. Among these, an oral presentation on June 8 will showcase the latest Phase 2 SOLSTICE trial data, originally accepted as a late-breaker poster.
The SOLSTICE trial (NCT05461170) is assessing the safety, tolerability, and efficacy of tobevibart and elebsiran for treating individuals with chronic hepatitis delta. The presentation will cover data from participants who have completed 12 and 24 weeks of chronic suppressive treatment, along with 48-week treatment data for six participants previously reported at the 2023 AASLD The Liver Meeting. Additional 24-week treatment data for all approximately 60 SOLSTICE participants is expected in the fourth quarter of 2024.
Dr. Carey Hwang, Vir’s Senior Vice President, Clinical Research and Interim Chief Medical Officer, emphasized the company's commitment to developing a transformative therapy for the estimated 12 million people living with chronic hepatitis delta. The upcoming presentations aim to provide further insights into virologic response rates, ALT normalization, and the durability of viral suppression.
Presentation Details:
-
Oral Presentation:
- Title: Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants (OS-127)
- Session: Viral hepatitis B/D: Therapy
- Date: Saturday, June 8
- Time: 11:45 a.m. CEST (5:45 a.m. EDT)
- Presenter: Tarik Asselah, M.D., Ph.D., Professor of Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, and Head of Viral Hepatitis at INSERM UMR1149, France
-
Poster Presentations:
-
Title: Tobevibart (VIR-3434), a monoclonal antibody, resistance analysis in participants with chronic HBV: Results from a Phase 1 single dose study (WED-376)
-
Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
-
Date: Wednesday, June 5
-
Time: Available from 8:30 a.m. CEST (2:30 a.m. EDT)
-
Presenter: Andrea Cathcart, Ph.D., Senior Director, Clinical Virology, Vir Biotechnology
-
Title: Pharmacokinetics and safety of the monoclonal antibody tobevibart (VIR-3434) administered as monotherapy or in combination with the small interfering RNA elebsiran (VIR-2218) in cirrhotic participants with mild hepatic impairment (WED-389)
-
Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
-
Date: Wednesday, June 5
-
Time: Available from 8:30 a.m. CEST (2:30 a.m. EDT)
-
Presenter: Sneha V. Gupta, Ph.D., Director, Clinical Pharmacology, Vir Biotechnology
-
A live webcast of the investor conference call will be available on Vir Biotechnology's investor website and archived for 30 days.
